Millions may be getting the wrong cholesterol test

New Delhi, India Jul 6, 2026 ALN: Millions of Americans undergo cholesterol testing annually, primarily to measure low-density lipoprotein (LDL) cholesterol, which is often labeled as "bad" cholesterol due to its association with cardiovascular diseases. However, a recent study conducted by researchers at Northwestern Medicine has raised questions about the effectiveness of this traditional approach. The study suggests that measuring apolipoprotein B (apoB) could provide a more accurate assessment of who requires aggressive treatment to mitigate the risk of heart attacks and strokes.

This research, published in the peer-reviewed journal JAMA, highlights a significant shift in how cholesterol management might be approached. The authors found that tracking apoB levels is more effective than relying solely on LDL or non-HDL cholesterol when determining the need for intensified cholesterol-lowering therapy, including the use of statins and other medications. This finding is crucial given the rising incidence of heart disease, which remains the leading cause of death in the United States and contributes significantly to care costs.

According to Ciaran Kohli-Lynch, the lead author of the study and an assistant professor of preventive medicine at Northwestern University Feinberg School of Medicine, the comprehensive analysis indicates that utilizing apoB testing to guide treatment could prevent a greater number of heart attacks and strokes compared to current practices. Furthermore, the study asserts that the benefits derived from apoB testing are achieved at a cost that is considered reasonable for U.S. care payers. Kohli-Lynch emphasizes that this is the first study to provide a thorough economic analysis supporting the cost-effectiveness of using apoB as a guide for cholesterol treatment.

The implications of these findings are profound. Heart disease, characterized by the buildup of plaques in artery walls due to cholesterol-carrying particles, leads to restricted blood flow and heightened risk of serious events, including heart attacks and strokes. As such, effective cholesterol management is critical not only for individual but also for reducing the overall burden on the care system.

Understanding the Role of ApoB in Cardiovascular Risk Assessment

Traditionally, care providers have depended on LDL cholesterol and non-HDL cholesterol levels to make decisions regarding the initiation or intensification of cholesterol-lowering treatments. While these tests provide valuable insights, they do not fully encapsulate an individual's overall cardiovascular risk profile. Kohli-Lynch notes that extensive research indicates that apoB is superior in identifying individuals at risk because it quantifies the total number of harmful cholesterol-carrying particles present in the bloodstream.

Apolipoprotein B is a protein that plays a crucial role in lipid metabolism and is a primary component of several lipoproteins that transport cholesterol in the blood. Unlike standard cholesterol tests, which measure cholesterol levels, apoB directly assesses the number of particles that can contribute to plaque formation in arteries. This makes apoB a more reliable indicator of cardiovascular risk, as it provides a clearer picture of the potential for plaque buildup.

Despite the growing body of evidence supporting the use of apoB, it remains underutilized in routine clinical practice. One of the barriers to its adoption is that measuring apoB necessitates an additional blood test beyond the standard cholesterol panel, which can increase both the financial burden on patients and the logistical challenges of obtaining the test. Kohli-Lynch's study specifically addressed whether the additional cost of apoB testing is justified in terms of outcomes.

Methodology: Computer Simulation to Compare Cholesterol Testing Strategies

To evaluate the potential benefits of incorporating apoB testing into clinical practice, the research team developed a computer simulation that represented a cohort of 250,000 U.S. adults who were eligible for statin therapy but did not have pre-existing cardiovascular disease. This simulation allowed the researchers to compare three different strategies for guiding cholesterol treatment:

• Using LDL cholesterol with a target goal of less than 100 mg/dL
• Using non-HDL cholesterol with a target goal of less than 118 mg/dL
• Using apoB with a target goal of less than 78.7 mg/dL

In cases where patients did not meet their target cholesterol levels, the model simulated treatment intensification by first prescribing stronger statins and, if necessary, adding ezetimibe, a medication that helps lower cholesterol levels. The researchers tracked outcomes over the patients' lifetimes, estimating the incidence of heart attacks and strokes, life expectancy, quality of life, and care costs associated with each treatment strategy.

The results of the simulation demonstrated that using apoB to guide treatment consistently yielded better outcomes compared to the LDL and non-HDL approaches. Specifically, the apoB strategy not only improved overall cardiovascular outcomes but also did so in a manner deemed cost-effective by the researchers. This finding is particularly significant given the ongoing discussions about care costs and the need for effective preventative measures in the face of rising rates of cardiovascular disease.

Implications of Updated Cholesterol Guidelines

The timing of this study is particularly relevant as care providers have access to a broader array of cholesterol-lowering medications than ever before. Earlier in the year, the American Heart Association, along with ten other medical organizations, released updated guidelines suggesting that many individuals should consider starting cholesterol-lowering therapy at younger ages. This shift underscores the necessity of accurately identifying those who would benefit most from intensive treatment.

Kohli-Lynch points out that as treatment guidelines evolve, the importance of precise testing methods becomes increasingly critical. The ability to accurately determine who is at risk for cardiovascular events can lead to more tailored and effective treatment plans, ultimately improving patient outcomes and reducing care costs.

In conclusion, the findings from this study advocate for a reevaluation of current cholesterol testing practices. By adopting apoB testing as a standard measure for guiding cholesterol management, care providers may be able to enhance patient care, prevent more cardiovascular events, and optimize care spending. The study, titled "Cost-Effectiveness of ApoB, Non-HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering Therapy," was supported by the American Heart Association Career Development Award, underscoring the importance of ongoing research in the field of cardiovascular .